top of page
Edible-Web.jpg

Understanding Different Methods of Ingestion:

A Guide to Edibles and Gummies

Among the approved dosage forms available to patients are oral cannabis products, including edibles and gummies. These products differ significantly from inhaled forms in terms of absorption, bioavailability, onset of action, peak plasma concentration, and duration of effect. Understanding these differences helps patients and clinicians make informed decisions regarding treatment selection.

What Are Cannabis Edibles and Gummies

Cannabis edibles and gummies are orally administered dosage forms containing defined quantities of cannabinoids, most commonly delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of cannabinoids in a lipid or polymer matrix (Iversen, 2020).

Oral Administration and Absorption

Following oral ingestion, cannabinoids undergo gastrointestinal absorption, primarily in the small intestine (Huestis, 2007).

​

Absorption is influenced by several variables, including:

  • Presence of dietary lipids

  • Gastric emptying time

  • Intestinal transit time

  • Formulation composition (Millar et al., 2018)
     

Compared with inhalation, oral absorption is slower and more variable, leading to delayed systemic exposure (Huestis, 2007).

First-Pass Metabolism and Bioavailability

A defining pharmacokinetic feature of oral cannabinoids is first-pass hepatic metabolism. After absorption, cannabinoids are transported via the portal vein to the liver, where extensive metabolism occurs before reaching systemic circulation (Huestis, 2007).

​

For THC, this process results in the formation of 11-hydroxy-THC, an active metabolite with psychoactive potency greater than parent THC (Grotenhermen, 2003).

​

Oral bioavailability of THC has been estimated at 4 to 12 percent, reflecting significant interindividual variability (Huestis, 2007). CBD exhibits similarly low and variable oral bioavailability due to extensive first-pass metabolism (Millar et al., 2018).

Onset of Action and Time to Peak Concentration

Oral cannabis products are characterised by a delayed onset of action relative to inhaled products.

Pharmacokinetic studies indicate
 

  • Onset typically occurs between 30 and 120 minutes post ingestion

  • Peak plasma concentrations may occur between 2 and 4 hours, depending on formulation and individual physiology (Huestis, 2007; Iversen, 2020)
     

This delayed onset is directly related to gastrointestinal absorption and hepatic metabolism, rather than pulmonary uptake.

Duration of Action 

Edibles and gummies generally produce a longer duration of effect compared with inhaled cannabis products.

​

Sustained plasma concentrations result from

  • Slow gastrointestinal absorption

  • Active metabolite formation

  • Redistribution of cannabinoids into adipose tissue (Grotenhermen, 2003)
    ​

Clinical observations suggest effects may persist for 6 to 8 hours or longer, depending on dose, cannabinoid profile, and patient metabolism (Iversen, 2020).

Variability in Response

Oral cannabinoid products demonstrate high individual variability, influenced by
 

  • Genetic differences in hepatic enzyme activity

  • Body composition

  • Gastrointestinal function (Millar et al., 2018)

Formulation Considerations

Formulation plays a critical role in cannabinoid delivery. Gummies and other edibles often incorporate lipids or emulsifiers to enhance oral absorption of lipophilic cannabinoids (Millar et al., 2018). This will allow:
 

  • Consistent cannabinoid concentration

  • Predictable release characteristics

  • Stability over the product shelf life (TGA, 2022)

Conclusion

Edibles and gummies represent an oral method of cannabinoid administration characterised by delayed absorption, significant first-pass metabolism, variable bioavailability, and prolonged duration of action. These features distinguish them clearly from inhaled cannabis products. Within a tightly regulated medicinal cannabis system, understanding these differences supports appropriate prescribing, patient education, and therapeutic consistency.

Disclaimer: This post is for informational purposes only and does not constitute medical or legal advice. Laws regarding prescription medicines vary by region, and readers should always consult with a qualified healthcare provider before using any prescription medication.

​References: Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360. Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemical Biodiversity, 4(8), 1770–1804. Iversen, L. (2020). The science of marijuana (3rd ed.). Oxford University Press. Millar, S. A., et al. (2018). A systematic review of cannabidiol dosing in clinical populations. British Journal of Clinical Pharmacology, 85(9), 1888–1900. Swift, W., et al. (2021). Patterns and experiences of medicinal cannabis use in Australia. Harm Reduction Journal, 18(70). Therapeutic Goods Administration. (2022). Therapeutic Goods Order No. 93 – Standard for medicinal cannabis. Australian Government.

bottom of page